Ensysce Biosciences Financials - Benzinga

Ensysce Biosciences Inc

ENSCNASDAQ

Trade with Public

Trade with Public

$0.5202

-0.0041-0.78%

At close: Aug 7, 5:00 PM EST

$0.5100

-0.0102-1.96%

After Hours: 7:59 PM EST

M&A: Cy Biopharma, Inc was acquired by Ensysce Biosciences (ENSC) on Thursday, August 6, 2026

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Ensysce Biosciences Financials

Ensysce Biosciences (ENSC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ensysce Biosciences Q1 EPS $(0.52) Beats $(0.73) Estimate, Sales $960.999K Miss $1.900M Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.73) by 28.77 percent. This is a 62.59 percent increase over losses of $(1.39) per share

Benzinga Newsdesk

PRO
Ensysce Biosciences Q4 EPS $(0.75) Misses $(0.70) Estimate, Sales $1.882M Beat $500.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent. This is a 74.14 percent increase over losses of $(2.90) per share

Benzinga Newsdesk

PRO
Ensysce Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate, Sales $493.104K Miss $700.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.84) by 52.66 percent. This is a 229 percent decrease over earnings of $1.00 per share

Benzinga Newsdesk

PRO
Ensysce Biosciences Q2 EPS $(0.79) Beats $(1.18) Estimate, Sales $1.371M Beat $650.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share

Benzinga Newsdesk

PRO
Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(3.02) by 53.97 percent. This is a 83.07 percent increase over losses of $(8.21) per share

Benzinga Newsdesk

Crude Oil Falls Over 3%; Philip Morris Earnings Top Views

Avi Kapoor